Owing to the frequent expression of CD30 and predominance of the non-GCB molecular subtype in EBV-positive DLBCL, therapies targeting CD30 and CD79b have shown promise in subgroup analyses [31, 32]. The gene discussed is CD79B; the disease is diffuse large B-cell lymphoma.